Surrozen (NASDAQ:SRZN) Stock, Quote.Headers.trade-ideas

Surrozen

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AEON

BIOR

BORR

CXAI

DOMA

DOYU

EIGR

GCTS

HGAS

HTCR

IMCC

INLX

IREN

IRON

MDIA

MESO

MMAT

NDRA

NVVE

ONDS

ORGS

OUST

PLSE

SBEV

SBFM

SGRP

SHCR

SRZN

TCOM

TPET

VSTE

ZPTA

Shares of  Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

pharma lab worker ai

Biotech

Equities

Health Care

Financing

Offerings

General

Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Phase 1a trial reveal promising safety, tolerability, and effects on liver function.

Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?

ALRM

AMRS

ATHX

ATNF

BLND

BRSH

BXSL

CARG

CLSK

CPRI

CPSI

DCTH

DNUT

EBIX

EDBL

EFXT

GDRX

GRTX

HLIT

HLLY

INVZ

LFMD

MDXH

MGNI

MGNX

MTNB

MVLA

NVAX

ORGN

ORGO

OSPN

PANL

PHXM

PLUG

RAMP

SENEA

SPRC

SSKN

STKL

Sunlight Financial Holdings, Inc. Class A Common Stock

SUNL

TASK

TAST

UIHC

VIRI

VTGN

XFOR

YELL

YETI

Gainers


	Edible Garden AG Incorporated  (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results.


Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Surrozen Inc

<p><strong>GE HealthCare Technologies&#39; </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gehc#NASDAQ">GEHC</a>) MIM Software recently announced the receipt of FDA clearance for performing Centiloid scaling for positron emission tomography (PET)-based amyloid imaging analysis and quantification.</p>
<p>With MIMneuro, a vendor-neutral solution, this new Centiloid scale tool is likely to be able to assist physicians in more accurately determining the density of amyloid plaque in a patient&#39;s brain. Amyloid PET radiotracers help visualize amyloid plaque density in patients being evaluated for Alzheimer&#39;s disease.</p>
<h2>Likely Trend of GEHC Stock Following the News</h2>
<p>Following the announcement, shares of the company moved nearly 1.7% north to $88.53 at yesterday&#39;s close.</p>
<p>GE HealthCare is one of the leading providers of medical technology, pharmaceutical diagnostics, and digital solutions with a focus on precision care. In March, GE Healthcare acquired MIM Software, which added AI-based solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics and research organizations worldwide. Owing to the strong potential for the diagnostic imaging market, we expect the market sentiment to remain positive around this news.</p>
<p>Meanwhile, GEHC currently has a market capitalization of $39.63 billion. It has an earnings yield of 4.91% is much higher than the industry&#39;s yield of negative (7.12)%. In the last reported quarter, GEHC delivered an earnings surprise of 2.04%.</p>
<h2>More on the GEHC&#39;s Centiloid Scaling Tool</h2>
<p>A significant number of people in the United States develop dementia, with Alzheimer&#39;s disease accounting for 60-80% of dementia cases. The condition affects memory, thinking and behavior, and symptoms typically start with mild cognitive impairment and eventually grow severe enough to interfere with daily tasks. A characteristic feature of this condition is the build-up of beta-amyloid protein in the brain, which is connected to tissue loss and cell death.</p>
<p>In order to assist physicians in identifying potential patients for amyloid-targeting therapies, PET imaging makes it possible to visualize and quantify amyloid protein. A global consortium of physicians and scientists created the Centiloid scale with the goal of harmonizing quantitative amyloid imaging analysis throughout radiotracers and organizations.</p>
<p>GE HealthCare&#39;s MIM Software now offers MIMneuro with Centiloid scaling, leveraging an automated workflow to help guide users through generating and understanding the quantitative result. The software takes the PET amyloid images, provides clinicians instructions to automatically generate quantitative results, and presents the data in a standardized report for clinicians to review alongside the images. As a result, clinicians can more easily access the quantitative data they need to evaluate patients.</p>
<p>MIMneuro with Centiloid scaling is the latest addition to GE HealthCare&#39;s comprehensive suite of products and solutions, which span the Alzheimer&#39;s disease care pathway from diagnosis through treatment monitoring.</p>
<h2>Favorable Industry Prospects for GEHC</h2>
<p>Per a report by Future Market Insight, the global brain imaging and neuroimaging market was estimated to be $13.7 billion in 2023 and is anticipated to surpass $22.4 billion by 2033 at a CAGR of 5.1%. The brain imaging and neuroimaging market is primarily driven by the rising incidence and prevalence of neurological disorders, increased awareness of neurodegenerative diseases, an increase in traumatic brain injuries, and increased applications of brain imaging and neuroimaging in clinical trials.</p>
<p>Given the market potential, the latest FDA clearance of MIM Software&#39;s Centiloid Scaling Tool is likely to provide a boost to GEHC&#39;s business.</p>
<h2>GEHC&#39;s Notable Developments</h2>
<p>In August, GEHC announced the receipt of the CE mark for its Vscan Air SL wireless handheld ultrasound system with Caption AI. The company also received the CE mark for the use of ECG-less cardiac computed tomography scanning on its Revolution Apex platform.</p>
<p>The company also collaborated with the University of California San Diego School of Medicine. The tie-up aims to investigate advanced magnetic resonance imaging protocols and techniques for female-specific diseases and conditions of the pelvis and develop comprehensive educational materials for clinicians.</p>
<h2>GEHC&#39;s Price Performance</h2>
<p>In the past six months, GEHC shares have lost 2.6% compared with the industry&#39;s decline of 12.4%. The S&amp;P 500 has gained 7.6% in the same time frame.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/51/78442.jpg?v=1728486434" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>GE HealthCare&#39;s Zacks Rank &amp; Stocks to Consider</h2>
<p>GEHC carries a Zacks Rank #3 (Hold) at present.</p>
<p>Some better-ranked stocks in the broader medical space are&nbsp;<strong>Universal Health Service</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;<strong>Quest Diagnostics&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;<strong>ABM Industries</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).</p>
<p>Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.</p>
<p>Universal Health Service has gained 56.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;48.1% rise.</p>
<p>Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.</p>
<p>Quest Diagnostics shares have gained 13.9% so far this year compared with the&nbsp;industry&#39;s&nbsp;17.9% rise.</p>
<p>ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.</p>
<p>ABM&#39;s shares have risen 27.4% so far this year compared with the&nbsp;industry&#39;s&nbsp;17% growth.</p>
<p><a href="https://www.zacks.com/stock/news/2338704/gehc-stock-rises-as-fda-clears-mim-software-s-centiloid-tool?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2338704">To read this article on Zacks.com click here.</a></p>


Earnings

Earnings Beats

Large Cap

Mid Cap

Analyst Ratings

GEHC

GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool

<p>Rosenblatt  analyst Barton Crockett   maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and maintains $635 price target.</p>


Price Target

NFLX

Rosenblatt Maintains Neutral on Netflix, Maintains $635 Price Target

<p>Rosenblatt  analyst Barton Crockett   maintains Sinclair (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) with a Neutral and raises the price target from $16.4 to $16.5.</p>


SBGI

Rosenblatt Maintains Neutral on Sinclair, Raises Price Target to $16.5

<p>Benchmark  analyst Matthew Harrigan   maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Buy and raises the price target from $220 to $250.</p>


TMUS

Benchmark Maintains Buy on T-Mobile US, Raises Price Target to $250

<p>Telsey Advisory Group  analyst Dana Telsey   maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.</p>


EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

US Postal Service Will Not Raise Stamp Prices In January

<p>TD Cowen  analyst Derrick Wood   maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Buy and lowers the price target from $31 to $27.</p>


CFLT

TD Cowen Maintains Buy on Confluent, Lowers Price Target to $27

Live On CNBC; Steve Weiss Adds Vertiv

ZVRA

Zevra Therapeutics Shares Resume Trade

<p>Financial giants have made a conspicuous bullish move on Deere. Our analysis of options history for Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) revealed 32 unusual trades.</p>
<p>Delving into the details, we found 56% of traders were bullish, while 34% showed bearish tendencies. Out of all the trades we spotted, 29 were puts, with a value of $1,287,729, and 3 were calls, valued at $706,047.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $430.0 for Deere, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Deere options trades today is 251.36 with a total volume of 3,334.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Deere's big money trades within a strike price range of $380.0 to $430.0 over the last 30 days.</p>
<h3>Deere Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726850889_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.3</td>
<td>$20.35</td>
<td>$21.25</td>
<td>$430.00</td>
<td>$637.5K</td>
<td style="text-align: right;">401</td>
<td style="text-align: right;">305</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$400.00</td>
<td>$181.5K</td>
<td style="text-align: right;">215</td>
<td style="text-align: right;">540</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.3</td>
<td>$4.0</td>
<td>$4.05</td>
<td>$390.00</td>
<td>$82.2K</td>
<td style="text-align: right;">729</td>
<td style="text-align: right;">322</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$38.75</td>
<td>$37.65</td>
<td>$38.2</td>
<td>$400.00</td>
<td>$76.4K</td>
<td style="text-align: right;">117</td>
<td style="text-align: right;">101</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$38.65</td>
<td>$38.0</td>
<td>$38.0</td>
<td>$400.00</td>
<td>$76.0K</td>
<td style="text-align: right;">117</td>
<td style="text-align: right;">121</td>
</tr>
</tbody>
</table>
</p>
<h3>About Deere</h3>
<p>Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.</p>
<h3>Where Is Deere Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 585,017, the DE's price is down by -0.4%, now at $408.1. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>What The Experts Say On Deere</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $425.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Deere, maintaining a target price of $425. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Deere with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Deere's Options: A Look at What the Big Money is Thinking

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Taiwan Semiconductor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TSM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 34 uncommon options trades for Taiwan Semiconductor.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 41%, bearish.</p>
<p>Out of all of the special options we uncovered, 11 are puts, for a total amount of $868,205, and 23 are calls, for a total amount of $2,542,785.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $200.0 for Taiwan Semiconductor over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Taiwan Semiconductor's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Taiwan Semiconductor's whale trades within a strike price range from $120.0 to $200.0 in the last 30 days. </p>
<h3>Taiwan Semiconductor 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726850884_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$22.3</td>
<td>$22.25</td>
<td>$22.25</td>
<td>$190.00</td>
<td>$712.0K</td>
<td>477</td>
<td>1.3K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$190.00</td>
<td>$378.0K</td>
<td>12.2K</td>
<td>2.6K</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.71</td>
<td>$2.7</td>
<td>$2.7</td>
<td>$160.00</td>
<td>$319.9K</td>
<td>11.6K</td>
<td>2.1K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$57.05</td>
<td>$54.05</td>
<td>$57.05</td>
<td>$120.00</td>
<td>$285.2K</td>
<td>590</td>
<td>0</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$9.95</td>
<td>$9.9</td>
<td>$9.95</td>
<td>$180.00</td>
<td>$177.1K</td>
<td>8.4K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Taiwan Semiconductor</h3>
<p>Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.</p>
<h3>Present Market Standing of Taiwan Semiconductor</h3>
<ul>
<li>Trading volume stands at 5,267,160, with TSM's price down by -0.23%, positioned at $175.82.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Taiwan Semiconductor with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Taiwan Semiconductor Unusual Options Activity For September 20

<p><strong>Analog Devices</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adi#NASDAQ">ADI</a>) recently announced its strategic alliance with Tata Group to advance the semiconductor ecosystem in India and leverage its products in Tata applications like electric vehicles and network infrastructure.</p>
<p>This collaboration is expected to be mutually beneficial and is a significant step in establishing a robust electronics manufacturing ecosystem in India for domestic and global consumption.</p>
<p>Tata Electronics, Tata Motors and Tejas Networks signed a Memorandum of Understanding with ADI to enhance strategic and business cooperation and explore opportunities for semiconductor manufacturing in India.</p>
<h2>Strategic Partnerships to Boost ADI&#39;s Prospects</h2>
<p>ADI&#39;s recent collaboration with <strong>Honeywell </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hon#NASDAQ">HON</a>) to digitize commercial spaces without replacing existing wiring, reducing costs and downtime is a noteworthy development.</p>
<p>Analog Devices announced a strategic partnership with Flagship Pioneering to speed up the development of a fully digitized biological world.&nbsp;</p>
<div class="chart_embed">
<h3>Analog Devices, Inc. Price and Consensus</h3>
<p><img alt="Analog Devices, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ed/1726758783.png" style="height:265px; width:620px" title="" /></p>
<p><span style="font-size:13px">Analog Devices, Inc. price-consensus-chart | Analog Devices, Inc. Quote</span></p>
<p>It teamed up with <strong>Taiwan Semiconductor</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) to secure long-term wafer capacity via Japan Advanced Semiconductor Manufacturing. This partnership, while ensuring a stable chip supply and facilitating rapid scaling and increased output to meet customer needs can be a game changer for ADI.</p>
<p>ADI&#39;s partnership with SambaNova Systems to rapidly deploy their enterprise-scale generative AI platform for enabling customer success might be a plus.</p>
</div>
<h2>Analog Devices Suffers From Stiff Competition</h2>
<p>Despite having a strong partner base, macroeconomic challenges remain a concern. Geo-political tensions and recessionary fears are major negatives.</p>
<p>ADI faces stiff competition from players like <strong>Texas Instruments</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txn#NASDAQ">TXN</a>), which is also making efforts to integrate generative AI capabilities into its products.</p>
<p>On a year-to-date basis, ADI has underperformed TXN, which gained 17.7%.</p>
<p>ADI shares have plunged 12.1% year to date against the broader Zacks Computer and Technology sector&#39;s return of 19.4%.</p>
<p>In the first half of fiscal 2024, ADI reported revenues of $4.67 billion, down 36% from the year-ago period. This underperformance can be firmly pointed toward the softness in the industrial, communications and automotive end markets.</p>
<h2>ADI&#39;s Q4 Guidance Positive</h2>
<p>For fourth-quarter fiscal 2024, ADI expects revenues of $2.40 billion (+/- $100 million), up 4% sequentially at the midpoint. The Zacks Consensus Estimate for the same is pegged at $2.41 billion, indicating a fall of 11.4% year over year.</p>
<p>ADI anticipates a non-GAAP operating margin of 41% (+/- 100 bps).</p>
<p>The company expects non-GAAP earnings to be $1.63 (+/- $0.10) per share. The consensus mark for the same is pegged at $1.63 per share, suggesting a decline of 18.9% year over year.</p>
<h2>Zacks Rank and Valuation</h2>
<p>ADI shares currently have a stretched valuation, as suggested by a Value Score of D.</p>
<p>Analog Devices stock is trading with a forward 12-month Price/Sales of 10.86X compared with the industry&#39;s 7.78X.</p>
<p>ADI currently carries a Zacks Rank #3 (Hold), implying that investors should wait for a favorable entry point.</p>
<p><a href="https://www.zacks.com/stock/news/2338731/adi-partners-with-india-s-tata-group-how-should-you-play-the-stock?cid=CS-BENZ-FT-analyst_blog|company_news_tech_sector-2338731">To read this article on Zacks.com click here.</a></p>


Macro Economic Events

Guidance

Economics

Tech

ADI Partners With India's Tata Group: How Should You Play the Stock?

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Robinhood Markets</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HOOD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Robinhood Markets.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 0% bullish and 100%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $859,484, and 3 are calls, for a total amount of $241,235.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $24.0 to $30.0 for Robinhood Markets during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Robinhood Markets stands at 18946.5, with a total volume reaching 4,903.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Robinhood Markets, situated within the strike price corridor from $24.0 to $30.0, throughout the last 30 days.</p>
<h3>Robinhood Markets 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726850879_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.2</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$30.00</td>
<td>$305.0K</td>
<td>1.4K</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.2</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$30.00</td>
<td>$174.4K</td>
<td>1.4K</td>
<td style="text-align: right;">771</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.15</td>
<td>$10.05</td>
<td>$10.15</td>
<td>$30.00</td>
<td>$173.5K</td>
<td>1.4K</td>
<td style="text-align: right;">599</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.15</td>
<td>$10.05</td>
<td>$10.15</td>
<td>$30.00</td>
<td>$126.8K</td>
<td>1.4K</td>
<td style="text-align: right;">426</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.09</td>
<td>$2.05</td>
<td>$2.05</td>
<td>$25.00</td>
<td>$102.5K</td>
<td>50.1K</td>
<td style="text-align: right;">634</td>
</tr>
</tbody>
</table>
</p>
<h3>About Robinhood Markets</h3>
<p>Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.</p>
<p>Following our analysis of the options activities associated with Robinhood Markets, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Robinhood Markets</h3>
<ul>
<li>Trading volume stands at 3,379,754, with HOOD's price down by -0.04%, positioned at $22.8.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 46 days.</li>
</ul>
<h3>Expert Opinions on Robinhood Markets</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $23.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Robinhood Markets, targeting a price of $27.<br />
&#x2A; An analyst from Barclays has elevated its stance to Equal-Weight, setting a new price target at $20. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Robinhood Markets options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


HOOD

Robinhood Markets Options Trading: A Deep Dive into Market Sentiment

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $117 price target.</p>


Reiteration

XOMA

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $117 Price Target

<p><strong>JP Morgan Chase &amp; Co. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) shares are trading higher on Friday. The bank reportedly started internal testing of a new credit card product.</p>
<p>The move comes as a part of plans to expand its offerings to U.K. consumers, <a href="https://www.bloomberg.com/news/articles/2024-09-20/jpmorgan-begins-testing-uk-credit-cards-in-latest-overseas-foray?srnd=homepage-Americas&amp;sref=TBDibEcD" target="_blank" rel="noreferrer noopener">reported </a>Bloomberg. The bank&#8217;s senior executives are said to be testing the credit cards within their mobile apps.</p>
<p>A person familiar with the matter said to Bloomberg that the product has been under development for over a year.</p>
<p>The new credit card will be added alongside investment products from JPMorgan&#8217;s digital wealth manager, Nutmeg, on its U.K. retail app, the report noted.</p>
<p>Notably, Nutmeg is the U.K.&#8217;s first and now largest digital wealth manager and serves over 200,000 <a target="_blank" href="https://www.chase.co.uk/gb/en/product/invest-with-nutmeg/" rel="noreferrer noopener">customers</a>, per the company&#8217;s website.</p>
<p>In July, the bank&nbsp;warned its 86 million customers to prepare for potential <a target="_blank" href="https://www.benzinga.com/government/24/07/39645336/largest-consumer-bank-chase-hints-increased-cost-to-consumers-for-everyday-banking-services" rel="noreferrer noopener">new charges on their bank accounts</a>.</p>
<p>This week, as per a report, JPMorgan is reportedly in talks with <strong>Apple </strong>about taking over its credit card program. The discussions began earlier this year <a target="_blank" href="https://www.benzinga.com/news/24/09/40907844/jpmorgan-in-talks-to-take-over-apple-credit-card-what-investors-need-to-know" rel="noreferrer noopener">and have advanced in recent weeks</a>.</p>
<p>Notably, <strong>Goldman Sachs </strong>is the current card issuer, but Apple and Goldman decided to part ways last year in their partnership, which included credit cards and savings accounts.</p>
<p>Investors can gain access to the stock via&nbsp;<strong>iShares U.S. Financial Services ETF&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and&nbsp;<strong>SPDR Select Sector Fund – Financial</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>).</p>
<p><strong>Price Action</strong>: JPM shares are down 0.04% at $210.40 at the last check Friday.</p>
<p><em>Image via Shutterstock</em></p>


Media

AAPL

iShares Trust Dow Jones US Financial Services Index Fund

JP Morgan Targets UK With Fresh Credit Card Offering: Report

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $195 to $207.</p>


Telsey Advisory Group Maintains Outperform on Ralph Lauren, Raises Price Target to $207

WIIM

SKYE

Skye Bioscience shares are trading lower amid sympathy with Novo Nordisk after the company reported results from its Phase2a trial of Monlunabant in obesity.

<p><strong>Nintendo ADR</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) and <strong>The Pokémon Company</strong> have filed a patent infringement lawsuit against Palworld developer <strong>Pocketpair</strong>, a case that could have significant ramifications for the <a href="https://www.benzinga.com/general/gaming/24/09/40859915/palworld-going-free-to-play-developer-weighs-bold-yet-difficult-move">indie game studio. </a></p>
<h3 class="wp-block-heading">The Patent At The Heart Of The Case</h3>
<p>According to <strong>Kiyoshi Kurihara</strong>, a Japanese patent attorney, the patent in question revolves around the game's monster-catching mechanic. </p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/asia/24/09/40945563/pok-mon-with-guns-nintendo-files-lawsuit-against-palworld-developer-over-alleged-patent-violations">&#8216;Pokémon With Guns&#8217;: Nintendo Files Lawsuit Against Palworld Developer Over Alleged Patent Violations</a></strong></p>
<p>Speaking to Yahoo Japan (<a href="https://automaton-media.com/en/news/whats-the-killer-patent-nintendo-is-suing-palworld-for-japanese-patent-attorney-offers-in-depth-analysis/">translated</a> by Automaton), Kurihara pointed to a "killer patent" that may be difficult to avoid for any game attempting to mirror the gameplay of Pokémon. </p>
<p>The divisional patent (Patent No. 7545191) describes a process in which the player aims a capture item at a character on the field, releases it based on their input, and determines if the capture succeeds, causing the monster to become the player's property.</p>
<p>&#8220;It seems like it would be hard to avoid if you want to make a Pokémon-like game, and it's easy to infringe if you're not careful,&#8221; Kurihara explained.</p>
<p>Since the indie game's release, people have compared Palworld's "Pals" to Pokémon, but the lawsuit focuses on patents rather than copyright infringement.</p>
<h3 class="wp-block-heading">A Legal Strategy In Motion</h3>
<p>Kurihara suspects Nintendo strategically planned the timing of its lawsuit. Authorities approved the four divisional patents in August, months after Palworld&#8217;s January release.</p>
<p>This delay might explain why Nintendo waited to announce its lawsuit, giving it the legal grounds to pursue Pocketpair after solidifying the patent claims.</p>
<p>The lawsuit&#8217;s impact on Palworld&#8217;s availability on platforms like Steam and Xbox remains uncertain. Nintendo's patents focus on the catching mechanics central to Pokémon. This could compel Pocketpair to alter its game or even remove key features.</p>
<h3 class="wp-block-heading">What's Next For Palworld?</h3>
<p>At its peak, Palworld shattered concurrent player records and saw massive sales. It reportedly earned so much that Pocketpair struggled to manage the influx of profits.</p>
<p>The developer moved quickly to capitalize on this success. It even formed a new company, Palworld Entertainment, in partnership with <strong>Sony Group Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) to further develop the brand.</p>
<p>Speculation is already swirling that Palworld will be making its way to PlayStation. Rumors suggest an announcement is imminent at the Tokyo Game Show, set to run from Sept. 26-29.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/40859915/palworld-going-free-to-play-developer-weighs-bold-yet-difficult-move">Palworld Going Free-To-Play? Developer Weighs Bold, Yet &#8216;Difficult&#8217; Move</a></li>
</ul>
<p><em>Image courtesy of Pocketpair.</em></p>


Gaming

Legal

NTDOY

Sony Group Corporation American Depositary Shares

SONY

Nintendo's 'Killer Patent' Could Crush Palworld's Monster-Catching Gameplay, Expert Warns

<p>Needham  analyst Joseph Stringer   reiterates Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and maintains $85 price target.</p>


APLS

Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target

<p>Needham  analyst Mike Matson   reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Hold.</p>


MASI

Needham Reiterates Hold on Masimo

Surrozen Inc (SRZN) is around the top of the Biotechnology industry according to InvestorsObserver. SRZN received an overall rating of 86, which means that it scores higher than 86 percent of all stocks. Surrozen Inc also achieved a score of 97 in the Biotechnology industry, putting it above 97 percent of Biotechnology sto

Should You Accumulate Surrozen Inc (SRZN) in Biotechnology Industry?

These Healthcare stocks are trading higher:-Xilio Therapeutics Inc (XLO) stock is trading at $1.48, an increase of $0.4, or 37.96%, on high volume.  Xilio Therapeutics Inc. gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $7.75

Healthcare Stocks Moving Monday: XLO, TPST, CNTB, NXL, EIGR, IRON, SRZN, VVOS

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Surrozen (SRZN – Research Report), Exelixis (EXEL – ...

Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)

Surrozen, Inc. (SRZN) has disclosed a new risk, in the Trade Secrets category. Surrozen, Inc. faces significant business risk as third parties may ...

Patent Battles: Surrozen, Inc. at Risk of Financial Instability Amid IP Challenges

Surrozen files to sell 1.09M shares of common stock for holders

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Surrozen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/srzn-stock-quote/"><strong>SRZN</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Surrozen reported earnings per share of -$4.24. This was above the analyst estimate for EPS of -$4.25.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/srzn-stock-earnings-surrozen-for-q1-of-2024/">SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024

Surrozen Non-GAAP EPS of -$4.24

Surrozen (SRZN) has provided an announcement. Surrozen, Inc. will experience a shift in its leadership as Tim Kutzkey, Ph.D., has announced his res...

Surrozen Announces Tim Kutzkey's Board Resignation

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Surrozen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/srzn-stock-quote/"><strong>SRZN</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Surrozen reported earnings per share of -$7.99. This was below the analyst estimate for EPS of -$2.79.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/srzn-stock-earnings-surrozen-for-q2-of-2024/">SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024

Surrozen GAAP EPS of -$7.99

AXSM

CNTB

EXEL

TPST

VVOS

Press Releases

Surrozen Provides Corporate Update on Clinical Programs

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Surrozen

Surrozen (SRZN) Forecast

Surrozen (NASDAQ:SRZN) Stock, Quote.Headers.trade-ideas